Literature DB >> 2014976

Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.

E D Ralph1, A M Khazindar, K R Barber, C W Grant.   

Abstract

Multilamellar liposomal amphotericin B (L-AmB) was generally less active in vitro against yeast strains than was amphotericin B-deoxycholate or free amphotericin B, although continual agitation of the broth disproportionately increased the activity of L-AmB. Time-kill studies also demonstrated a slower onset of action of L-AmB and supported the hypothesis that liposomes may act as reservoirs for free amphotericin B, which is the active moiety.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2014976      PMCID： PMC244966          DOI： 10.1128/AAC.35.1.188

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations.

Authors:  S Jullien; J Brajtburg; J Bolard
Journal:  Biochim Biophys Acta       Date:  1990-01-15

2.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

3.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

5.  Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B.

Authors:  R S Weber; G Lopez-Berestein
Journal:  Laryngoscope       Date:  1987-08       Impact factor: 3.325

6.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

7.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; L S Frankel; K Mehta
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

8.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Authors:  R L Juliano; C W Grant; K R Barber; M A Kalp
Journal:  Mol Pharmacol       Date:  1987-01       Impact factor: 4.436

9.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.

Authors:  S Jullien; A Contrepois; J E Sligh; Y Domart; P Yeni; J Brajtburg; G Medoff; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191
View more
  14 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

5.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Authors:  E M Johnson; J O Ojwang; A Szekely; T L Wallace; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.

Authors:  D Caillot; P Chavanet; O Casasnovas; E Solary; G Zanetta; M Buisson; O Wagner; B Cuisenier; A Bonnin; P Camerlynck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

9.  Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats.

Authors:  K R Reuhl; M Vapiwala; M T Ryzlak; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

Authors:  J S Hostetler; K V Clemons; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.